PL2838548T3 - Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania - Google Patents

Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania

Info

Publication number: PL2838548T3
Authority: PL; Poland
Prior art keywords: hla class; deficient cells; proteins; expressing; cells capable
Prior art date: 2012-04-17

Application number

PL13714128.9T

Other languages

English (en)

Inventor

David W. Russell

Roli K. Hirata

Original Assignee

University Of Washington Through Its Center For Commercialization

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-17

Filing date

2013-03-15

Publication date

2024-02-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48045753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2838548(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-15 Application filed by University Of Washington Through Its Center For Commercialization filed Critical University Of Washington Through Its Center For Commercialization

2024-02-05 Publication of PL2838548T3 publication Critical patent/PL2838548T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Developmental Biology & Embryology (AREA)
Cardiology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Transplantation (AREA)
Plant Pathology (AREA)

PL13714128.9T 2012-04-17 2013-03-15 Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania PL2838548T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261625314P	2012-04-17	2012-04-17
PCT/US2013/032058 WO2013158292A1 (en)	2012-04-17	2013-03-15	Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof

Publications (1)

Publication Number	Publication Date
PL2838548T3 true PL2838548T3 (pl)	2024-02-05

Family

ID=48045753

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13714128.9T PL2838548T3 (pl)	2012-04-17	2013-03-15	Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania

Country Status (12)

Country	Link
US (2)	US20150056225A1 (pl)
EP (2)	EP2838548B1 (pl)
JP (4)	JP2015514421A (pl)
AU (1)	AU2013249820C1 (pl)
CA (2)	CA2870571A1 (pl)
DK (1)	DK2838548T5 (pl)
ES (1)	ES2959382T3 (pl)
FI (1)	FI2838548T3 (pl)
HU (1)	HUE063231T2 (pl)
PL (1)	PL2838548T3 (pl)
PT (1)	PT2838548T (pl)
WO (1)	WO2013158292A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3116902T (pt) *	2014-03-11	2020-04-03	Cellectis	Método para gerar células t compatíveis para transplante alogénico
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr)	2014-10-14	2016-04-21	Dana Farber Cancer Inst Inc	Molécules d'anticorps de pd-l1 et leurs utilisations
WO2016069283A1 (en) *	2014-10-31	2016-05-06	The Trustees Of The University Of Pennsylvania	Altering gene expression in cart cells and uses thereof
EP3215623A4 (en) *	2014-11-06	2018-09-26	President and Fellows of Harvard College	Cells lacking b2m surface expression and methods for allogeneic administration of such cells
WO2016094679A1 (en)	2014-12-10	2016-06-16	Regents Of The University Of Minnesota	Genetically modified cells, tissues, and organs for treating disease
WO2016112779A1 (en) *	2015-01-17	2016-07-21	Zhejiang University	Modified cells evoking reduced immunogenic responses
WO2016123100A1 (en)	2015-01-26	2016-08-04	Fate Therapeutics, Inc.	Methods and compositions for inducing hematopoietic cell differentiation
CA2988854A1 (en) *	2015-05-08	2016-11-17	President And Fellows Of Harvard College	Universal donor stem cells and related methods
EP3328418A1 (en)	2015-07-29	2018-06-06	Novartis AG	Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
JP7534070B2 (ja)	2015-11-04	2024-08-14	フェイトセラピューティクス，インコーポレイテッド	造血細胞分化を誘導するための方法および組成物
KR20180066262A (ko)	2015-11-04	2018-06-18	페이트 세러퓨틱스, 인코포레이티드	만능 세포의 유전자 조작
WO2017106656A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
US10889643B2 (en)	2016-01-11	2021-01-12	Universität Zürich	Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
KR102528977B1 (ko) *	2016-04-27	2023-05-03	유니버시티 헬스 네트워크	펩타이드-hla 복합체 및 그 제조 방법
BR112019014257A2 (pt) *	2017-01-13	2020-04-28	Univ California	método para gerar uma célula-tronco pluripotente hipoimunogênica, célula-tronco pluripotente hipoimunogênica humana, método para produzir uma célula pluripotente hipoimunogênica, e ss-2 microglobulina
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
US20200172628A1 (en)	2017-06-22	2020-06-04	Novartis Ag	Antibody molecules to cd73 and uses thereof
BR112019027104A2 (pt)	2017-06-22	2020-08-18	Novartis Ag	moléculas de anticorpo para cd73 e usos das mesmas
CA3067914A1 (en)	2017-06-30	2019-01-03	Cellectis	Cellular immunotherapy for repetitive administration
WO2019081983A1 (en)	2017-10-25	2019-05-02	Novartis Ag	CD32B TARGETING ANTIBODIES AND METHODS OF USE
EP3684399A1 (en)	2017-12-29	2020-07-29	Cellectis	Method for improving production of car t cells
WO2019129850A1 (en)	2017-12-29	2019-07-04	Cellectis	Off-the-shelf engineered cells for therapy
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
JP2021534813A (ja) *	2018-07-13	2021-12-16	ロタールゲルメロート	非免疫原性の操作された組織ならびにそれを製造および使用する方法
WO2020018691A1 (en) *	2018-07-18	2020-01-23	The General Hospital Corporation	Modified t cells and methods of their use
CN110819592A (zh) *	2018-08-13	2020-02-21	赛元生物科技(杭州)有限公司	一种通用供体干细胞及其制备方法
US11162079B2 (en)	2019-05-10	2021-11-02	The Regents Of The University Of California	Blood type O Rh-hypo-immunogenic pluripotent cells
JPWO2021157685A1 (pl) *	2020-02-07	2021-08-12
CN116322749A (zh)	2020-08-19	2023-06-23	安斯泰来制药有限公司	特异性结合至非天然存在的修饰的Fc受体的人非天然存在的修饰的IgG的Fc区
EP4200023A4 (en)	2020-08-23	2024-10-30	Applied Stemcell Inc	HLA-F-MODIFIED CELLS AND METHODS
CN114276995A (zh) *	2020-09-28	2022-04-05	未来智人再生医学研究院(广州)有限公司	一种表达ctla-4阻遏分子的多能干细胞及其衍生物
CN114457021A (zh) *	2020-10-30	2022-05-10	未来智人再生医学研究院(广州)有限公司	一种表达cd47抗体的多能干细胞及其衍生物与应用
CN114525257A (zh) *	2020-10-30	2022-05-24	未来智人再生医学研究院(广州)有限公司	一种表达Tim-3阻断物的多能干细胞或其衍生物及应用
CN114525254A (zh) *	2020-10-30	2022-05-24	未来智人再生医学研究院(广州)有限公司	一种表达fgf-21的多能干细胞或其衍生物及应用
CN114517184A (zh) *	2020-10-30	2022-05-20	未来智人再生医学研究院(广州)有限公司	一种表达adipsin的多能干细胞或其衍生物及应用
CN114457022A (zh) *	2020-10-30	2022-05-10	未来智人再生医学研究院(广州)有限公司	一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
US11459372B2 (en)	2020-11-30	2022-10-04	Crispr Therapeutics Ag	Gene-edited natural killer cells
US11661459B2 (en)	2020-12-03	2023-05-30	Century Therapeutics, Inc.	Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es)	2020-12-18	2023-03-22	Century Therapeutics Inc	Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
EP4271798A1 (en)	2020-12-30	2023-11-08	CRISPR Therapeutics AG	Compositions and methods for differentiating stem cells into nk cells
US20240158742A1 (en)	2021-03-09	2024-05-16	Riken	Method for producing hypoimmunogenic retinal pigment epithelial cells
EP4334437A1 (en)	2021-05-03	2024-03-13	Astellas Institute for Regenerative Medicine	Methods of generating mature corneal endothelial cells
EP4334435A1 (en)	2021-05-07	2024-03-13	Astellas Institute for Regenerative Medicine	Methods of generating mature hepatocytes
WO2023154799A1 (en)	2022-02-14	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Combination immunotherapy for treating cancer
WO2024003349A1 (en)	2022-07-01	2024-01-04	Novo Nordisk A/S	Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
WO2024044134A1 (en)	2022-08-23	2024-02-29	Astellas Institute For Regenerative Medicine	Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5158881A (en)	1987-11-17	1992-10-27	Brown University Research Foundation	Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
US5574205A (en)	1989-07-25	1996-11-12	Cell Genesys	Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991010470A1 (en)	1990-01-08	1991-07-25	Brown University Research Foundation	Devices and methods for enhanced delivery of active factors
AU9076191A (en) *	1990-11-21	1992-06-25	Massachusetts Institute Of Technology	Mice having beta 2 microglobulin gene disruption
US5837234A (en)	1995-06-07	1998-11-17	Cytotherapeutics, Inc.	Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5869270A (en) *	1996-01-31	1999-02-09	Sunol Molecular Corporation	Single chain MHC complexes and uses thereof
EP0995798A1 (en) *	1998-10-24	2000-04-26	Novimmune Sa	Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
US20040225112A1 (en)	2003-05-06	2004-11-11	Crew Mark D.	Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
WO2007091078A2 (en)	2006-02-10	2007-08-16	Axordia Limited	Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
US8105831B2 (en)	2007-03-09	2012-01-31	University Of Washington	Parvoviral production of HLA homozygous cells
CA3157027A1 (en) *	2010-07-21	2012-01-26	Sangamo Therapeutics, Inc.	Methods and compositions for modification of a t-cell receptor gene
CA3205636A1 (en) *	2011-04-20	2012-10-26	University Of Washington Through Its Center For Commercialization	Beta-2 microglobulin-deficient cells

2013
- 2013-03-15 PL PL13714128.9T patent/PL2838548T3/pl unknown
- 2013-03-15 WO PCT/US2013/032058 patent/WO2013158292A1/en active Application Filing
- 2013-03-15 US US14/391,328 patent/US20150056225A1/en not_active Abandoned
- 2013-03-15 EP EP13714128.9A patent/EP2838548B1/en active Active
- 2013-03-15 ES ES13714128T patent/ES2959382T3/es active Active
- 2013-03-15 CA CA2870571A patent/CA2870571A1/en active Pending
- 2013-03-15 DK DK13714128.9T patent/DK2838548T5/da active
- 2013-03-15 JP JP2015507006A patent/JP2015514421A/ja active Pending
- 2013-03-15 HU HUE13714128A patent/HUE063231T2/hu unknown
- 2013-03-15 EP EP23173587.9A patent/EP4253409A3/en active Pending
- 2013-03-15 FI FIEP13714128.9T patent/FI2838548T3/fi active
- 2013-03-15 AU AU2013249820A patent/AU2013249820C1/en active Active
- 2013-03-15 PT PT137141289T patent/PT2838548T/pt unknown
- 2013-03-15 CA CA3085032A patent/CA3085032A1/en active Pending
2019
- 2019-02-06 JP JP2019019289A patent/JP7130571B2/ja active Active
- 2019-06-14 US US16/441,889 patent/US20190365876A1/en active Pending
2022
- 2022-08-24 JP JP2022132891A patent/JP7531925B2/ja active Active
2024
- 2024-07-24 JP JP2024118377A patent/JP2024144548A/ja active Pending

Also Published As

Publication number	Publication date
PT2838548T (pt)	2023-10-13
EP2838548A1 (en)	2015-02-25
JP2024144548A (ja)	2024-10-11
DK2838548T5 (en)	2024-08-05
US20190365876A1 (en)	2019-12-05
JP2019068856A (ja)	2019-05-09
EP4253409A3 (en)	2023-12-06
EP4253409A2 (en)	2023-10-04
ES2959382T3 (es)	2024-02-26
JP7531925B2 (ja)	2024-08-13
CA2870571A1 (en)	2013-10-24
AU2013249820B2 (en)	2017-07-20
CA3085032A1 (en)	2013-10-24
JP7130571B2 (ja)	2022-09-05
HUE063231T2 (hu)	2024-01-28
JP2015514421A (ja)	2015-05-21
US20150056225A1 (en)	2015-02-26
FI2838548T3 (fi)	2023-10-02
WO2013158292A1 (en)	2013-10-24
DK2838548T3 (en)	2023-08-21
AU2013249820A1 (en)	2014-10-23
EP2838548B1 (en)	2023-07-19
JP2022162047A (ja)	2022-10-21
AU2013249820C1 (en)	2018-10-25

Publication	Publication Date	Title
DK2838548T3 (en)	2023-08-21	Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
IL286784A (en)	2021-10-31	Compositions of protein and antibody
IL272324B (en)	2022-06-01	Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming
HK1211620A1 (en)	2016-05-27	Natural killer cells and uses thereof
HK1214304A1 (zh)	2016-07-22	用於在細胞中表達蛋白質的方法和產品
SG11201500799YA (en)	2015-03-30	Hla g-modified cells and methods
EP2802647A4 (en)	2015-11-25	ISOLATED HUMAN LUNG PREVIEW CELLS AND USES THEREOF
HK1210790A1 (en)	2016-05-06	Modified factor polypeptides and uses thereof
EP2833431C0 (en)	2023-08-30	TEST BATTERY BOX AND TEST BATTERY
HK1207662A1 (en)	2016-02-05	Cell suspension and use thereof
HK1205523A1 (en)	2015-12-18	Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
EP3080855A4 (en)	2017-07-26	Electrochemical cells and components thereof
HK1205185A1 (en)	2015-12-11	Methods and composition related to brown adipose-like cells
HK1252801A1 (zh)	2019-06-06	經修飾的紅細胞前體細胞及其用途
SG11201510209SA (en)	2016-01-28	Cell populations, methods of transdifferention and methods of use thereof
EP2844272A4 (en)	2015-11-04	METHOD AND COMPOSITIONS FOR INCREASING RED BLOOD BODIES
EP3019203A4 (en)	2017-04-26	Endothelial cell genes and uses thereof
SG11201406771PA (en)	2014-11-27	Stem cell preparations and methods of use
HK1208811A1 (en)	2016-03-18	Novel arterivirus protein and expression mechanisms
HK1210436A1 (en)	2016-04-22	Novel cell compositions and methods
EP2810330A4 (en)	2015-07-15	COMPOSITE ELECTROLYTE CONSISTING OF ENTIRELY STABILIZED ZIRCONIA AND PARTIALLY STABILIZED ZIRCONE
GB201221083D0 (en)	2013-01-09	Electrochemical cells and components thereof
GB201211627D0 (en)	2012-08-15	Depilatory strips and their manufacture
GB201216536D0 (en)	2012-10-31	Light harvesting cells, devices and materials and methods of making
GB201320632D0 (en)	2014-01-08	Electrochemical cells and components thereof